SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GlycoGenesys GLGS (formerly SafeScience SAFS)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (45)9/9/2005 9:22:46 AM
From: Findit  Read Replies (1) of 56
 
GLGS - Scimitar is initiating a “BUY’ of GlycoGenesys, Inc. (GLGS: NASDAQ). We project a FY05 target
price of $2.25 for GLGS’s stock. If collaboration is consummated by the end of 2005 with a
major pharmaceutical or biotechnology company to develop and commercialize GLGS’s GCS-
100 compounds, then our FY06 target price would be upgraded to $3.50 – 4.00.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext